Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Hemolink: HMSL said the data reports from 2 trials of Hemolink for CABG will be delayed. The company said the delay was due to "administrative complexities" of

Hemosol Inc. (HMSL; TSE:HML), Toronto, Ontario
Product: Hemolink
Business: Blood products/substitutes
Therapeutic

Read the full 128 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE